A regulated medical category with no access to standard payment tools is a conversion problem most teams walk away from. Shopify Payments blocked. Subscription tools incompatible. Manual recurring plan management. In a market where patients are making health decisions, a confused checkout isn't cart abandonment. It's a patient who needed treatment walking away because the system felt unreliable.
Trim operates under GPhC registration, UK prescriber oversight, and clinical compliance requirements that block the default e-commerce stack. The platform had disconnected payment flows, no automated dosage progression tracking, and high support volume from patients lost between checkout and their treatment plan.
The design problems ran deeper than infrastructure. Visual hierarchy across the treatment pages gave equal weight to every element. Clinical disclaimers competed with CTAs. Dosage information sat at the same size and weight as promotional copy. Nothing guided the eye toward the next step. On mobile, where most patients browse, the layout collapsed into a wall of equally-weighted text blocks with no clear reading path.
The competitive context raised the stakes. 76 pharmacies now offer GLP-1 medications online. The medications are identical. The prices are similar. Every competitor site follows the same visual pattern: clinical white backgrounds, stock photography, dense paragraph-heavy layouts with no hierarchy between sections. The opportunity was in the design layer. A clear visual system, deliberate typographic hierarchy, and conversion-sequenced layouts could separate Trim from 75 near-identical competitors without sacrificing a gram of medical credibility.
The scope confirmed this wasn't a surface-level fix. Every patient touchpoint from first click through ongoing treatment management needed to hold the same standard: clinical authority and commercial warmth, simultaneously, across desktop and mobile, without losing either side.
Architecture before aesthetics. Full sitemaps, user flow mapping, and subscription flows mapped before a single screen was built. The brief never changed: make a medically complex subscription feel like buying anything else online, across every touchpoint from homepage to app.
The homepage established the visual hierarchy system that carried across every other page. Clinical proof from 200 patients (91% hunger reduction, 96% weight loss at six months, 84% mild side effects only) sat in the first scroll at headline weight. Real patient names underneath at a smaller, lighter secondary level. Emma lost 20kg. Amber lost 75lbs. Trustpilot rating anchored next to the hero headline. The hierarchy was deliberate: proof elements large and high-contrast, supporting clinical detail smaller and softer, CTAs isolated with generous spacing so nothing competed for attention at the decision point.
The colour system solved the credibility problem visually. Gradient purples separated Trim from the clinical-white pattern every competitor defaults to. Warm enough to feel like a DTC brand. Controlled enough to feel medically serious. The palette ran through every touchpoint: homepage, treatment pages, quiz, subscription dashboard, app. One visual language. No context switching between screens.
The consultation quiz was built as a 5-step form flow. Each step used a single-column constrained layout (no wider than 500px) with one question per view. Progress indicators kept momentum visible. Labels were de-emphasised, input fields prominent. The 3-step approval visual (Consultation, Treatment Plan, Next-Day Delivery) collapsed medical subscription complexity into one scannable left-to-right sequence using size and weight to show progression, not just numbering.
The blocked payment stack was invisible to patients. The checkout carried the same typography, colour system, and spacing scale through every step. No visual break between eligibility and payment. Patients moved through without registering a handoff.
The companion app extended the visual system past checkout. Treatment tracking, dosage reminders, plan management, all using the same typographic hierarchy, colour palette, and spacing logic from the website. The app wasn't a separate product bolted on. It was the same design system rendered on a smaller screen. Marketing landing pages for paid acquisition stripped the main site to a single conversion objective: proof, promise, CTA. Same trust architecture, tighter layout, no navigation distractions.
Full website, marketing landing pages, consultation flow, subscription system, and companion app. Six weeks. Every screen held the same standard: clinical trust and commercial conversion, simultaneously.
Six weeks from kickoff to launch-ready. Every deliverable shipped within the window.
Retention increased 35% after the subscription interface was restructured around treatment stages rather than generic billing cycles. Visual hierarchy showed patients exactly where they were in their dosage plan. Large type for current stage, muted smaller type for upcoming stages, clear colour differentiation between active and completed cycles. Cancellations dropped because the interface made the plan legible at a glance.
Sign-up completion increased 40% after the checkout flow was rebuilt with a single-column layout, consistent brand typography, and no visual break between the eligibility step and payment. One input per row, generous vertical spacing between fields, labels de-emphasised so patient attention stayed on the action, not the instruction.
Support volume fell because the interface surfaced the information patients used to call about. Dosage progression, plan changes, next steps, all visible inside the subscription UI with clear typographic hierarchy between primary information (current dose, next adjustment date) and secondary detail (clinical notes, prescriber information).
The app closed the retention loop. Post-purchase, patients tracked their treatment inside the same visual system they bought from. Same gradient palette, same type scale, same spacing logic. No context switch between web and mobile. The Trustpilot rating reflected it: 4.8 from 427 reviews in a market where the medication is identical across 76 competitors. The design system became the only moat.
